News & Events



MicuRx forms collaboration with Pfizer to develop antibiotics

Biotechnology companies MicuRx Pharmaceuticals in California and Cumencor Pharmaceuticals in China that is applying MicuRx's technology to develop antibiotics formed collaborating with Pfizer to develop antibiotics for drug-resistant tuberculosis in China. Under the deal, Pfizer will provide an upfront payment, funding for the discovery and preclinical development of antibiotics, and payments linked to the development and commercialization of any antibiotics developed through the partnership.

Mucurx was founded by Dr Zhengyu Yuang who was the founding scientist of Vicuron Pharmaceuticals Inc. (formerly Versicor), and Senior Vice President of Research, before Vicuron was acquired by Pfizer at the end of 2005. While in Vicuron, Dr. Yuan had identified 7 clinical development candidates. Dr. Yuan has pioneered the discovery of peptide deformylase (PDF) inhibitors as a new class of antibacterial agents which entered the human clinical trials. Prior to joining Vicuron, Dr. Yuan has worked at Syntex, Affymax, and GlaxoWellcome.

He received his Ph.D. degree in Biochemistry from Cornell University and B.S. degree in Chemistry from Fudan University.

中国《生物医药‘十二五’发展规划》即将出炉

肝癌致癌基因取得重大发现

南通大学举行《北美华人生物医药协会归国代表团演讲会》

BIO Welcomes Zhangjiang Hi-Tech Park and China Medical City

US-China Collaboration to battle the oil spill

Smart underpants become personal monitor

中国公布《国家中长期人才发展规划纲要》

中国重新强调科技创新“举国体制”

Pain, Adenosine and Acupuncture

苏州工业园区第三批生物医药领军人物

New tooth growing from stem cell

Charles River Plans to Acquire WuXi AppTec for 1.6 B

Page: 1 | 2 | 3 | 4 | 5 |